source
- Novo’s stock tumbles after two-year GLP-1 boom as AI drug-discovery startups land huge funding roundsNovo’s shares, which peaked above $140 in June 2024 during a surge in demand for its GLP-1 drugs Ozempic and Wegovy, have fallen sharply over the past two years. The decline reflects a broader mark…
- RNAi biotech ADARx raises $446 million in IPO, secures $89 million from AbbVieADARx Pharmaceuticals priced its initial public offering at $17 per share, selling more than 26 million shares to raise about $446.3 million. The company also received an additional $89 million th…